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Abstract
Regenerative therapies aim to develop novel treatments to restore tissue 
function. Several strategies have been investigated including the use of biomedi-
cal implants as three-dimensional artificial matrices to fill the defect side, to 
replace damaged tissues or for drug delivery. Bioactive implants are used to 
provide growth environments for tissue formation for a variety of applications 
including nerve, lung, skin and orthopaedic tissues. Implants can either be 
biodegradable or non-degradable, should be nontoxic and biocompatible, and 
should not trigger an immunological response. Implants can be designed to 
provide suitable surface area-to-volume ratios, ranges of porosities, pore inter-
connectivities and adequate mechanical strengths. Due to their broad range of 
properties, numerous biomaterials have been used for implant manufacture. To 
enhance an implant’s bioactivity, materials can be functionalised in several ways, 
including surface modification using proteins, incorporation of bioactive drugs, 
growth factors and/or cells. These strategies have been employed to create local 
bioactive microenvironments to direct cellular responses and to promote tissue 
regeneration and controlled drug release. This chapter provides an overview of 
current bioactive biomedical implants, their fabrication and applications, as well 
as implant materials used in drug delivery and tissue regeneration. Additionally, 
cell- and drug-based bioactivity, manufacturing considerations and future 
trends will be discussed.
Keywords: biomaterials, bioactive biomedical implants, stem cells, drug delivery, 
manufacturing
1. Introduction to bioactive implants
Implants are man-made devices that are fabricated for the implantation inside 
body to replace or support a biological structure, together with delivering drugs and 
monitoring body functions. They can remain in the body temporarily or perma-
nently [1]. To date, biomedical implants are used not only as sensory devices [2]; 
brain and neural devices including neuronal, cochlear and retinal implants [3, 4]; 
subcutaneous implants [5]; cardiovascular devices such as vascular grafts, stent, 
heart valves, pacemakers [3]; sutures and wound dressings [6]; spinal [7] and den-
tal implants [8]; cosmetic [9] and structural implants [10] including rods, braces, 
craniofacial, hip and knee replacements; but also as ophthalmic devices including 
glasses and contact lenses as well as insulin delivery devices [6].
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In recent years, scaffolds made of synthetic or natural polymers were developed to 
regenerate damaged or deteriorated tissues, or to deliver drugs to specific locations. 
Scaffolds are three-dimensional (3D) structures that mimic the native extracellular 
matrix (ECM) of tissues and provide a substrate for cell adhesion and proliferation.
These biomedical implants can be made of bioactive materials. The term “bioac-
tive” means that a material can affect its surrounding tissue biologically. Scaffolds 
can include molecules that promote a biological response in the region where they 
are implanted. Moreover, cells can be included in these scaffolds to promote healing 
and regeneration, as they naturally secrete growth factors and cytokines [11].
The risks related to the surgery during the placement or removal of the implant 
include infection and implant failure. Also, inflammation reaction against the 
material or rejection needs to be taken into consideration [1]. Here, we report what 
it is known about bioactive biomedical implants, their desired properties and their 
applications, focusing on the techniques and materials used for their fabrication. 
We further provide an overview of cell-based and drug-based implants, implant 
manufacture and its considerations.
2. Biomaterials for implants in drug delivery and regenerative therapies
To assist native tissue regeneration or/and replacement, implants are made of 
biomaterials, which support cell and tissue growth through cell adhesion, prolifera-
tion and differentiation, prevent unwanted cell and tissue growth, tailor tissue 
response and prevent immunological responses [12].
Biomaterials have been used for controlled drug delivery systems, sutures and 
adhesives including biodegradable and non-biodegradable materials, cardiovascular 
grafts, reconstructive and orthopaedic implants, ophthalmic devices such as cor-
neas and contact lenses, and dental implants [13]. Various types of materials have 
been used to produce biomedical implants. These include bioceramics, polymers, 
metals and composites, which are further discussed below. Table 1 summarises 
current biomedical applications for biomaterials.
Application Material References
Ophthalmic applications (contact 
lenses, intraocular lenses)
Silicones, hydrogels [14]
Cardiovascular applications 
(vascular prostheses, artificial 
valves, stents, cardiac-assisted 
pumps, blood bags and catheters)
Polymers, metals and ceramics; polyurethane 
(PU); polyesters (PE); polybutesters (PBE); 
polypropylene (PP) and PTFE; stainless steel
[15–21]
Central nervous system and 
peripheral nervous system 
(scaffolds for nerve regeneration)
Polycaprolactone (PCL), silk, collagen [11, 22–26]
Orthopaedic applications (total hip 
replacement, hip arthroplasty, total 
knee arthroplasty, bone screws, 
orthodontic brackets and wires; 
bone fillers and scaffolds as bone 
replacements)
Chromium, cobalt, molybdenum, nickel, titanium 
and zirconium alloys, ultrahigh molecular 
weight polyethylene (UHMWPE), Ti-6Al-4V, 
ceramic-coated steels, stainless steel, copper; 
natural polymers like collagen, chitosan, alginates, 
synthetic polymers, ceramics like bioglasses, 
hydroxyapatite and beta-TCP; poly(l-lactic acid) 
(PLLA); poly(lactic acid), poly(lactic-co-glycolic 
acid) (PLGA), polycaprolactone (PCL)
[11, 12, 14, 
27–33]
Table 1. 
Examples of biomedical applications for currently used biomaterials.
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2.1 Bioceramics
Ceramics are chemically inert and possess low thermal and electric conductivity 
as well as physical properties, which make them a suitable material glass for bio-
medical implants [34, 35]. Bioceramics are osteoinductive and osteoconductive and 
possess mechanical properties like native bone. Their use as biomedical implants 
prevents the transmission of diseases and immunogenicity. To date, bioceramics are 
utilised for dental, periodontal, maxillofacial and orthopaedic applications [36]. 
In comparison to non-resorbable bioceramics, degradable ceramics exhibit lower 
mechanical strength. Their chemical and physical composition determines their 
biological response [37].
Ceramics produced from aluminium, zirconium and titanium oxides possess 
bending, tensile and compressive strength at least 3 times higher than natural 
bone and are used mainly for pin-type dental implants and root- and endosteal 
plate forms [38]. The first zirconia implants were reported in the 1970s. These 
implants exhibited the ability to integrate into bone tissue, accumulate less 
plaque and provide improved aesthetics compared to titanium implants [39, 
40]. Hence, titanium-zirconium alloys, also called Straumann Roxolid or Roxolit 
(TiZr1317), are often used as dental implants due to their enhanced mechani-
cal properties and osseointegrative properties that are often used as dental 
implants [41].
Calcium phosphate-based bioceramics such as tricalcium phosphate (TCP) 
are similar in chemical composition to the inorganic phase natural bone tissue. 
TCP exhibits better biodegradation, restorability and bioactivity in vivo than 
hydroxyapatite and is commonly used for orthopaedic, dental and maxillofacial 
applications. Complete resorption of orthopaedic implants fabricated from TCP 
was reported after up to 2 years in the rat tibia and for the formation of cancellous 
bone [42].
Amorphous or low crystalline hydroxyapatite (HAp) is bioactive and bioresorb-
able. The preparation of synthetic HA at high temperatures results in high crystal-
linity. Biodegradation and resorbability of HAp are very slow. HAp bioceramics are 
commonly used for small defects in the case of bone loss or fractures of the tibia, 
calcaneus and vertebra. HAp is not employed for load-bearing bone applications 
because of its poor mechanical properties. The modification of HAp with stron-
tium, magnesium and silicon ions resulted in enhanced mechanical and biological 
properties [43]. Improved bioresorbability was achieved by zinc—[44] and manga-
nese—[45] substitution of HAp.
Dicalcium phosphates (DCP) are biodegradable ceramics composed of calcium 
phosphates and water. DCPs are widely added to material compositions to modify 
their physical properties. Dehydrated DCP is known as brushite, which is used in 
tibial plate and distal metaphysis bone fractures [46].
Historically, ceramics have been used as dental and orthopaedic implant mate-
rials. However, compared to other material classes, ceramics have not 
been used extensively as implant materials due to their limited load-bearing 
capacity [14].
2.2 Polymers
Polymers are macromolecules that consist of covalently bonded repeating units, 
which can be of the same (homopolymers) or different (co-polymers) molecule 
type [27]. A variety of natural and synthetic polymers are used as soft tissue trans-
plants, facial prostheses, denture, hip and joint replacements as well as medical 
adhesives, sealants and coatings [14].
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Polymers are commonly selected based on their physical characteristics, compo-
sition, and mechanical properties; how easily they can be modified and moulded; 
their heat and electric conductivity as well as their ability to integrate into and 
attach to native tissue [47].
2.2.1 Natural polymers
Natural polymers possess similar properties to native tissues. They are non-toxic 
and exhibit protein binding-sites and biochemical moieties that are important for 
tissue regeneration. However, natural polymers are often associated with immu-
nological reactions, low mechanical strength and degradation at body temperature 
limiting their usability [14].
One of the most commonly used natural polymers is collagen. More than twenty 
different collagens are known in connective tissues such as bone, tendon, skin, 
cartilage and ligaments of the ECM of different species. Collagen type I is the main 
component in bone, skin and tendon, whereas type II is found in articular cartilage. 
Because of its abundance in nature, its importance for tissue homeostasis and 
growth, collagen has been investigated as material for bone, cartilage, tendon, skin 
and blood vessel regeneration [11]. In the clinic, collagen is used for the generation 
of dermal tissue, neo-tissue formation and wound healing [14]. Further natural 
polymers are chitosan, hyaluronic acid, fibrin and silk.
Silk, or silk fibroin, is a naturally occurring polymeric protein produced by 
insects and worms. The protein content gives rise to silk’s biocompatibility and its 
high tensile strength making it an ideal biomaterial for biomedical applications as 
gels, sponges and films [11, 48–53]. Silk composites fabricated from silk-chitosan 
and silk-hydroxyapatite have been used to improve silk’s elasticity, degradation and 
porosity [54, 55].
Hyaluronic acid (HA), a non-adhesive glycosaminoglycan (GAG), occurs mostly 
in connective, epithelial, and neural tissue [56]. HA is commonly used as hydro-
gel for the regeneration of bone, cartilage and the vascular system and for drug 
delivery [11].
Chitosan is a biodegradable polysaccharide produced through partial deacety-
lation of chitin. Chitosan scaffolds exhibit similar properties to naturally occurring 
GAGs, leading to their bioactivity, and support cellular adhesion [11, 57]. It has 
been investigated as scaffold material in combination with collagen and HA, as well 
as PCL for bone, cartilage and nerve regeneration [11].
2.2.2 Synthetic polymers
Synthetic polymers were developed with tailored physical and chemical prop-
erties depending on the desired application to overcome limitations of natural 
polymers. Synthetic polymers are linear, branched or cross-linked depending on 
their molecular arrangement [58] and possess amorphous or crystalline struc-
tures [27]. In addition, synthetic polymers are cheaper in production and enable 
improved functionality [11]. Commonly used synthetic polymers are poly(lactic 
acid-co-glycolic acid) (PLGA), polyglycolic acid (PGA), polylactic acid (PLA), 
polycaprolactone (PCL) and poly-hydroxybutyrate (PHB) [11, 27, 59, 60].
PGA, PLA and PCL are used for sutures, interference screws, fixation plates 
for meniscal repair and craniomaxillofacial fixtures and 3D scaffolds. However, 
they are known to induce inflammatory responses and are limited in mechanical 
integrity and controlled degradation. Hence, metal/polymer composites such as 
Mg/PCL have been developed [27]. Biodegradable synthetic polymers are chosen 
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based on the required physical, chemical and mechanical material characteristics 
(Table 2).
2.3 Metals and alloys
Due to their mechanical properties, the ease of their processing and the pos-
sibility to sterilise them, metals and alloys are ideal materials for biomedical 
implants [34].
Metals are commonly used as load-bearing orthopaedic implants such as wires, 
screws, fixation plates, artificial joints for hips, knees, shoulders and ankles, as well 
as for dental, cardiovascular and craniofacial applications [14].
Novel magnesium alloys have been investigated for orthopaedic and cardiovas-
cular applications [84, 85]. Combining magnesium alloys with aluminium or rare 
earth metals improves their mechanical properties [86, 87]. However, the accumu-
lation of these elements is associated with neurotoxicity and hepatotoxicity [88]; 
hence, these alloys are not suitable for biomedical applications. Instead, extensive 
research is carried out to develop nontoxic magnesium alloys [89], such as Mg-Si 
and Mg-Sr alloys [90].
Titanium alloys are among the most commonly used metal alloys [91] due 
to their biocompatibility [92] and corrosion resistance [93]. Their composition 
Synthetic polymer Application References
Poly(l-lactic acid) (PLLA); poly 
(d-lactic acid) (PDLA)
Sutures, drug delivery, vascular grafts, bone 
screws, fixation pins, dermal filler for facial 
atrophy (Scultra™)
[11, 61]
Poly(lactic-co-glycolic acid) (PLGA) Drug delivery [11, 62]
Polycaprolactone (PCL) Long-term implant, maxillo-cranial facial 
implant; drug release
[11, 63]
PCL-gelatin, PCL-chitosan, 
PCL-collagen
Tissue regeneration [60, 64, 65]
Poly-para-dioxanone (PPD) Internal fracture fixation, medical implant as 
films, foams and moulded scaffolds
[47, 66, 67]
Low-density polyethylene (LDPE), 
high-density polyethylene (HDPE)
Total hip arthroplasty and treatment of 
osteolysis as polymer-ceramic composites; 
rhinoplasty surgery
[68–71]
Poly(methyl methacrylate) (PMMA) Orbital medical implants, rhinoplasty, 
cranioplasty, bone cement in hip joint 
replacement, dental implant for restoration and 
aesthetics
[72–76]
Polydimethylsiloxane (PDMS) Enclosing implantable electronic devices 
and sensors, medical implants, oesophagus 
substitutes, catheters, shunts, blood pumps and 
peacemakers
[77–80]
Polyamides (PA), e.g., nylon and 
nylon-composites
Sutures, fabrication of dentures; scaffold 
materials and nanofillers for bone regeneration
[81, 82]
Carbon nanotubes (CNT) and 
composites
Metal coatings for load-bearing musculoskeletal 
implants to improve surface porosity, reduce 
metal ionisation and promote the formation of 
hydroxyapatite
[83]
Table 2. 
Synthetic polymers commonly used for the fabrication of biomedical implants.
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and microstructure vary depending on their elemental composition [94]. The 
mechanical properties of B-titanium alloys have a Young’s modulus like bone 
but possess a low fatigue strength. Their mechanical properties can be enhanced 
through the addition of silicon dioxide, zirconium dioxide and Yttrium oxide. 
Furthermore, to increase their wear resistance, titanium alloys are surface treated. 
Pure titanium alloys are used in pacemaker cases, ventricular devices, implantable 
drug pumps, screws and staples in spinal surgery, dental implants and craniofacial 
implants. Ti-6Al-4V alloys are used in hip and knee replacements and dental 
implants. Due to the release of aluminium and vanadium ions, which can cause 
neurological conditions such as Alzheimer’s, Ti-6Al-4V alloys are not considered 
safe for long-term use. β-Titanium alloys substituted with stabilising elements like 
zirconium, tantalum and molybdenum are safer compared to Ti-6Al-4V [27], and 
alternative titanium alloys, vanadium free Ti-6Al-7Nb and Ti-5Al-2.5Fe, are being 
developed [95].
Titanium has become the material of choice for implants; however, com-
ponents of prosthetics are still manufactured from gold alloys, stainless steel, 
nickel-chromium alloys and cobalt-chromium alloys [35]. Cobalt chromium 
alloys enable the fabrication of customised grafts including subperiosteal 
implants. They are mainly composed of cobalt, chromium and molybdenum, 
which give rise to corrosion resistance and mechanical properties [96, 97]. 
Stainless steel alloys such as iron-chromium-nickel-based alloys are used as 
orthopaedic implants such as ramus blade, ramus frame, stabiliser pins and some 
mucosal inserts. Due to its nickel content, these alloys possess a low corrosion 
resistance and induce immunological reactions in patients with nickel allergies 
[34, 38].
3. Implant properties
Implant materials should possess adequate chemical and physical properties to 
allow for host tissue infiltration and nutrient transport; biocompatibility to avoid 
immunological responses; and corrosion resistance, degradation and bioresorb-
ability to enable normal cellular activity and controlled implant degradation [14, 27, 
98]. In addition, temporary implants should possess a highly interconnected porous 
structure to allow cell migration and nutrient and waste transport, provide suitable 
surface topography to support cell adhesion and growth, as well as allow for the 
release of bioactive molecules if applicable [5, 11, 12].
Mechanical properties like Young’s Modulus, tensile, compressive and shear 
strength, yield strength and fatigue strength are required to ensure uniform stress 
distribution, to minimise the movement or fracture of the implant [34].
3.1 Surface properties
Surface properties influence cell adhesion and cellular and tissue responses. 
Surface tension determines the wettability by a wetting fluid, such as blood or 
water [11, 34]. Implant surfaces are also categorised by roughness, texture and the 
orientation of irregularities [38, 99]. The surface textures can vary from concave or 
convex. Concave surface textures occur due to additive treatments such as hydroxy-
apatite coatings, whereas convex surfaces are created through etching and blast-
ing. Furthermore, implant surfaces can either be isotropic, meaning that implant 
properties are independent from the measurement direction, or anisotropic, which 
means properties are directionally dependent [12, 34].
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3.2 Corrosion and degradation of implants
3.2.1 Metal corrosion
Corrosion is the involuntary breakdown of metals by an electrochemical reac-
tion and through the loss of ions from the metal surface in an acidic, an alkaline or 
a neutral environment. It is one of the most common reasons for implant failure 
[98]. Table 3 summarises the types of corrosions that have been observed in metal 
implants [98–100].
Magnesium for example corrodes faster with an increase of impurities such as 
nickel, copper and iron [101]. The higher the purity of magnesium, the slower its 
corrosion rate. However, pure magnesium is not suitable for medical implants due 
to its mechanical characteristics. Instead, calcium is used for the grain refinement in 
magnesium alloys [102]. Orthopaedic implants fabricated from Mg-Ca alloys were 
observed to corrode over a 3-month period after bone formation [103]. Magnesium’s 
mechanical properties can also be enhanced through Mg-Zn with calcium, manga-
nese, yttrium or zirconium [104, 105]. Mg-Zn alloys withstand galvanic corrosion 
and biocorrosion in vitro; however, biocorrosion in vivo resulted in a 2 mm/year 
reduction of a Mg-Zn alloy used as rods in femur shafts [106].
3.2.2 Polymer degradation
Polymer degradation, or biodegradation, occurs through a process called hydro-
lysis. The polymer surface is attacked by organisms, which secrete enzymes break-
ing down ester bonds in macromolecules. The resulting smaller polymer molecules 
are further converted into carbon dioxide and water. The process of biodegradation 
varies for each polymer [27, 107, 108]; however, all polymers lose their mechani-
cal integrity. To date, PGA, PLA and PLGA among others have been explored for 
biomedical implants [27]. Their degradation into non-toxic by-products made them 
favourable materials for temporary biomedical implants [109]. Poly(l-lactic) acid 
Corrosion type Explanation Biomedical implants
Crevice 
corrosion
• Occurs in narrow regions
• Metal ions create localised positive 
charge in the crevice
• Interfaces between screws/plates 
and bone
Pitting 
corrosion
• Occurs in implants with small surface pit
• Metal ions react with chloride ions 
resulting in rough surfaces
• Orthopaedic and dental implants
Galvanic 
corrosion
• Occurs due to electrical gradient between 
Co-Cr alloys, Ni-Cr, Ag-Pd,  
Au-ternary Ti
• Oral/dental implants
• Screws and nuts
Corrosion 
fatigue and 
fretting
• Occurs due to cyclic stress • Bone cement
• Femoral implants
• Bone plates and screws at the bone-
stem interface
• Stem-cement interfaces of modular 
hip implant
Table 3. 
Types of corrosions observed in metallic biomedical implants.
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(PLLA) has been shown to induce inflammatory responses in vivo upon degradation 
due to its high crystallinity; hence, poly(d, l-lactic acid) (PDLA) was synthesised 
[110, 111].
PLGA degrades into acidic moieties, which in higher concentrations can affect 
the microenvironment of the implant’s surrounding tissue. This can be especially 
important for drug delivery applications, where pH-sensitive drugs are used [11]. By 
increasing the amount of poly(glycolic acid) (PGA) compared to poly(lactic acid) 
(PLA) in PLGA, the degradation rate is reduced; hence, less acidic by-products are 
formed [11].
3.3 Biocompatibility
Biocompatibility indicates a desired response of the implant to its biological 
surrounding [34] and depends on biodegradability and corrosion. The ISO 10993 
standard series is used to assess biocompatibility of medical grade materials and 
medical devices [112]. Test categories investigate the materials’ cytotoxicity, 
sensitization, irritation, toxicity, implantation and biodegradation [71]. Materials 
that meet these criteria include noble metals and titanium, their alloys, cobalt-based 
alloys, but also alumina, zirconia, quartz, fused silica, bioglass, silicon, biocompat-
ible polymers like epoxies, silicones, polyurethanes, polyimides, silicon-polyimides, 
polycyclic-olefins, silicon-carbons, and liquid crystal polymers [113].
3.4 Foreign body response
Foreign body response (FBR) is a non-specific immune reaction of the body to 
implanted materials. This inflammatory reaction can happen in response to surgical 
implantation of biodegradable or non-biodegradable materials present in medical 
devices or implants [114, 115]. FBR can modulate the safety and/or function of the 
implanted material. FBR is characterised by distinct phases, namely onset, progres-
sion and resolution [116] (Figure 1). The onset starts with the surgical implantation 
of the biomaterial, for example, subcutaneously, which causes local tissue damage 
[117]. Upon tissue damage, vessel permeation to cells and proteins increases and 
coagulation occurs where inflammatory mediators like vascular endothelial growth 
factor (VEGF) plays an important role along with neutrophils and macrophages to 
initiate the wound healing process. In parallel, angiogenic factors stimulate local 
vasculature.
FBR comprises of a biomaterial-dependent and biomaterial-independent reac-
tion (Figure 1). If biodegradable materials are present, the FBR will persist until the 
material is fully degraded. With non-degradable or long-term implants, a fibrotic 
capsule creating a barrier between the material and the body will form.
Progression of FBR depends on the material’s surface chemistry and wettabil-
ity [118], where protein, antibody and macrophage adsorption can vary due to 
the material’s intrinsic properties. Additionally, fibrinogen can be adsorbed by 
the implant altering its structure. During FBR’s progression, leukocyte extraver-
sion occurs from the blood vessels. These migrate towards the foreign body. 
Consequently, polymorphonuclear neutrophils (PMNs) are activated, which 
recruit cells including macrophages to the site. Macrophage activation leads to the 
recruitment of fibroblasts, monocytes and more PMNs [116], which ultimately 
increases production of extracellular matrix and hence implant encapsulation and 
fibrosis.
Phagocytosis occurs from the onset when antibodies are non-specifically 
adsorbed by the biomaterials, thus recruiting phagocytes. During progression, 
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phagocytosis by macrophages is continuously promoted through the degradation of 
the material through biodegradation.
Material particles too large to be phagocyted cause the formation of larger mul-
tinucleated cells by fusion of macrophages. These so-called foreign body giant cells 
possess an irregular shape with more than 20 nuclei dispersed randomly. Giant cells 
will usually disappear once the foreign body is fully degraded. Surface roughness 
and surface/volume ratio of the implant can influence the adhesion of macrophages 
or prevalence of fibrosis [114].
As part of FBR, fibrosis is critical in tissue engineering, since capsule for-
mation can prevent the diffusion of molecules (e.g., drugs) and continuous 
fibrosis formation can lead to capsule shrinkage thus affecting the implant 
structure [119]. It has been shown that inhibition of TGF-β can reduce capsule 
formation [120].
Finally, resolution of the foreign body response involves the degradation of the 
biomaterial or removal of the non-degradable material.
3.4.1 Immunomodulation for circumventing the foreign body response
Biomaterials’ characteristics partly determine the body’s immune response to 
the implant. Implant pore size and morphology are critical since they can allow 
immune cells and macromolecules to interact with the implant. In addition, degra-
dation products derived from implants like scaffolds and medical devices, as well as 
their constantly changing surfaces, can trigger the immune response [121]. Recent 
implants can carry therapeutic cells. These cellular implants provoke an immune 
response due to encapsulated cells, posing further challenges besides biomaterial 
compatibility and design [122–124].
Figure 1. 
Foreign body response to implant materials. Sequence of events and responses leading to the fibrous capsule 
formation and foreign body giant cell formation (adapted from [117]).
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Polymers such as collagen, alginate, chitosan, polyethylene glycol, polyvinyl 
alcohol and polyurethane are used in several implantable products that may have an 
inherent biocompatibility. Understanding how these polymer’s chemical and physi-
cal properties can be used to either avoid immune response or modulate it, while 
improving their functionality, is crucial for the advancement of these systems [121].
Strategies to circumvent the FBR include changing the biomaterial’s surface 
properties like wettability, its chemical moieties, and surface charge, because they 
affect protein adhesion to the biomaterial [121, 125].
To create more hydrophilic surfaces, monolayers of hydrophilic polymers such as 
polyethylene glycol (PEG) and polyethylene oxide (PEO) are added, thus prevent-
ing protein adsorption altogether [126]. The deposition of chemical moieties like 
amino (▬NH2), carboxyl (▬COOH), hydroxyl (▬OH), and methyl (▬CH3) groups 
allows the modulation of cellular adhesion influencing inflammatory cell infiltra-
tion and macrophage response affecting the fibrotic capsule thickness around the 
implant [121]. Surface charge is important for the FBR immunomodulation. There 
have been contradicting reports on how exactly neutral, positive or negative charges 
reduce the inflammatory response connected to the FBR. Generally, negatively 
charged surfaces tend to inhibit the immune response through reduced cell adhe-
sion [127].
Moreover, implant topography including texture, shape and size has shown to 
trigger an FBR [121]. Therefore, several manufacturing techniques like particles, 
assembled monolayers and photolithography are used to create variety of shapes, 
sizes and surface topographies [128, 129]. Surface roughness at the nanoscale 
can modulate protein adsorption [130], while variations in surface roughness at 
microscale affect cells directly [131]. For example, the inflammatory response of 
titanium used for dental or orthopaedic applications can be decreased by altering its 
surface nano-and microstructures via physical or chemical procedures [121].
Macrophage interaction with differently shaped biomaterials demonstrated 
preferred internalisation of nanorods via pinocytosis compared to nanospheres. 
Additionally, sharper cornered surfaces led to more acute immune responses than 
smoother surfaces [121, 132]. Moreover, spherical alginate capsules of 1.5 mm or 
greater were reported to be more biocompatible than their smaller, non-spherical 
comparators, demonstrating that larger, rounder, smoother capsules could diminish 
the FBR [133].
The use of decellularised ECM as scaffolds by removing immunogenic compo-
nents to avoid an acute response but keeping the original structure has been stud-
ied. While decellularised ECMs contribute to a pro-regenerative environment [134], 
it has been discussed that the immune response modulation still depends on the 
original tissue from which the ECMs have been obtained. Therefore, this option still 
presents a potential solution with more research needed to advance its understand-
ing, manufacturing and impact [134].
The incorporation of bioactive molecules such as adhesion molecules, drugs and 
growth factors to promote immunological interaction with the host attenuating 
its response has been investigated. Bioactive molecules bound to the biomaterial 
for controlled release aiding tissue regeneration [125] include proinflammatory 
molecules like prostaglandins [135] and anti-inflammatory molecules like cytokines 
[136]. Combining their delivery with glucocorticoids improved tissue regenera-
tion and attenuation of inflammation [137]. In recent years, the encapsulation of 
immune cells that act as producers or inducers of specific biological responses to 
reduce inflammation and/or induce repair has been investigated as immunomodula-
tion strategy [125]. Examples include the encapsulation of MSCs to decrease the 
fibrosis in FBR [138] or the encapsulation of macrophages to mediate pro-angiogenic 
activation [139].
11
Biomedical Implants for Regenerative Therapies
DOI: http://dx.doi.org/10.5772/intechopen.91295
Overall, understanding the fundamental biological systems associated with FBR 
and the structural, physical and chemical properties of biomaterials will lead to 
new designs and strategies allowing to circumvent or work together with the natural 
body’s response towards implants.
4. Bioactive implants
Implants can be bioactive, inducing an alteration to the surrounding tissue, 
by their own biomaterials imparting this alteration to the surrounding tissue, by 
releasing a drug (or drugs) inducing bioactivity, or by containing cells that can 
produce bioactive molecules. In the following sub-sections, we discuss the implant 
bioactivity induced by drugs and cells implicating in drug delivery and in tissue 
regeneration.
4.1 Bioactive implantable and injectable drug delivery systems
Bioactive implants may incorporate active substances including small chemicals, 
peptides, proteins, hormones and even cells, which will have a therapeutic function 
in the human body. For drug delivery, these systems are commonly administered via 
parenteral route by injection or implantation. There are also implantable drug deliv-
ery systems that can be administered via ocular administration or via surgical pro-
cedures such as brain implants (e.g., Gliadel®). Implantable drug delivery systems 
are designed to slowly release the active substance(s) that they carry, thus avoiding 
repetitive injection. The active substance is delivered at a consistent predictable 
rate creating a drug release profile. This avoids peaks and troughs in the drug-blood 
level, which is common for non-long acting injectable products (e.g., intravenous 
solutions). Implantable drug delivery systems can be also injected subcutaneously, 
intramuscular or via other sites including intra-articular. They include implants 
and suspensions of micro- or nano-particles. Typically, these systems are preferred 
when the active substance has a poor absorption by other means of administration 
or a short half-life. The major advantages of such systems are improved pharmaco-
kinetics, control of the drug release rate, and enhanced patient acceptability due to 
the reduction of side effects by maintaining the drug-blood level constant and by 
decreasing administration frequency [140, 141].
Sustained drug release is obtained via diffusion of the active substance through a 
biomaterial matrix, or released through biomaterial biodegradation, or a combina-
tion of both mechanisms. To date, commonly used biomaterials for drug delivery 
are either biodegradable like PCL and PLA or non-biodegradable like polydimeth-
ylsiloxane, polyethyl vinyl acetate, or titanium alloy [141]. Several approaches have 
been developed to produce implantable drug delivery systems [142] and to control 
the drug release. These include (i) using diffusion via membrane permeation, either 
porous or semi-porous membranes; (ii) controlling drug release by matrix diffusion 
using porous polymers; (iii) reservoir systems, where the drug is encapsulated in an 
inner reservoir; and (iv) actively releasing the drug from the implant via osmotic 
pressure, electric current, vapour pressure, hydrolysis or ultrasound activation.
Typically, simple rod-like solid implants, produced by hot melt extrusion 
processes using biodegradable polymers like PLA, PCL, PLGA and PEVA, 
often display a biphasic drug release kinetics showing a burst release due to the 
drug being deposited on the surface or near the surface of the implant, fol-
lowed by a zero-order kinetics reflected by drug diffusion, matrix erosion, or 
a combination of both depending on the polymeric biomaterial used. Table 4 
summarises drug release systems that are currently commercially available or 
B
iom
ateria
ls
12
System Product Drug Manufacturer Indication Clinical status
Implants [143–148] Zoladex® (PLGA solid rod, 1 × 10 mm) Goserelin (up to 3 month 
release)
AstraZeneca Prostate cancer Approved by FDA
Nexplanon® (radiopaque PEVA solid 
rod)
Etonogestrel (release up to 
3 years)
Merck Contraception Approved by FDA
ITCA 650 (Medici technology, former 
Duros®)
Exenatide (release up to 
2 years)
Ipsen Type 2 diabetes Clinical Phase III/
NDA
MK-8591 (PCL solid implant) EFdA (long-term release) Merck HIV treatment and 
prevention
Pre-clinical/Phase I
Microparticles 
[149–151]
Risperdal Consta® (PLGA microspheres) Risperidone Janssen Antipsychotic Approved by FDA
Decapeptyl SR® (PLGA microspheres) Triptorelin Debiopharm/Ferring/
Ipsen
Prostate cancer Approved by FDA
Sandostatin LAR® (PLGA microspheres) Octreotide Novartis Acromegaly Approved by FDA
Bydureon® (PLGA microspheres) Exenatide Amylin/AstraZeneca Type 2 diabetes Approved by FDA
Vivitrol® (PLGA microspheres) Naltrexone Alkermes Opioid/alcohol dependence Approved by FDA
In situ hydrogels [152, 
153]
Eligard® (Atrigel® technology) Leuprolide acetate Sanofi-Aventis Prostate cancer Approved by FDA
Posidin® (Sabre® technology) Bupivacaine Durect/Sandoz Postoperative pain Clinical Phase III/
NDA
Relday® (Sabre® technology) Risperidone Durect/Zogenix Schizophrenia/bipolar 
disorder
Phase I
Sublocade® (Atrigel® technology) Buprenorphine Indivior Severe opioid use disorder Approved by FDA
Summarised are current systems that are commercially available or under development. Table was adapted from [140, 141, 148, 151, 153].
Table 4. 
Drug delivery systems as implantable and injectable depots.
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under development. There are numerous advantages to using implants in drug 
delivery such as the possibility of removal after treatment, the consistent and 
predictable drug release, and versatility in manufacture using various bioma-
terials. However, there are potential disadvantages of this dosage form, where 
often a specialised device (e.g., trocar) and technique are needed for implanta-
tion and removal requires minor surgical procedures. Additionally, there may be 
complications in locating the implant for removal since it can migrate from its 
original location. From a commercialisation point of view, this type of bioactive 
implant may require complex regulatory and commercial strategies for market 
approval [154].
Injectable drug delivery systems, such as particulate suspensions or hydrogels 
like in situ forming gel depots, are designed from biodegradable biomaterials, 
injected (e.g., subcutaneous, intramuscular), form a depot, erode when in contact 
with body fluids, and release the drug by diffusion and erosion [149]. Injectable 
depots are not designed to be retrieved. Examples of injectable depots are micro- or 
nano-scale particles, where the drug is encapsulated within the polymer matrix. 
The polymeric particles are commonly prepared from biodegradable materials (e.g., 
PLGA, PCL, or silica) since the intent is to deliver the depot system once by injec-
tion, let it erode and release the drug with time.
Choosing the polymer grade, type and combining polymer types can help tune 
the drug release as necessary [149, 154]. Key points in preparing these bioactive 
depots are the choice of the biomaterial (biodegradable/erodible), the physico-
chemical properties of drug to be encapsulated (i.e., hydrophobic or hydrophilic), 
the drug loading needed to deliver the therapeutic dose, and the inherent phar-
macokinetics of the drug. This will inform the choice of manufacturing methods, 
often by emulsification. Common polymers used in these preparations are PLGA 
and PLA, where their long safety records deem these polymers as preferred, even 
though some minor inflammatory responses can still be reported [150].
Hydrogels, prepared from different types of biomaterials (e.g., hyaluronic acid, 
polyesters and chitosan) have been extensively investigated as carriers for sustained 
drug release [152, 155]. In situ forming hydrogels as injectable depots pose major 
advantages over other drug release systems since they allow for rapid, painless and 
easier administration through smaller needle sizes. These biodegradable in situ 
depots are of low viscosity prior injection and solidify into a gel or solid depot after 
injection, typically due to a specific trigger depending on the chemistry of the 
chosen biomaterial [153].
4.2 Bioactive cell-based implants as drug delivery systems
Before commercialising a cellular implant, it needs to be approved by FDA’s 
Cellular, Tissue and Gene Therapies Advisory Committee. The Committee evaluates 
the safety and effectiveness of cellular implants for the reconstruction, repair or 
replacement of damaged tissues [156].
Cell-based drug delivery systems can be defined as technologies capable of 
treating diseases using living cells to deliver the therapeutic bioactive molecules 
in the body, as either transport system or as production units [157]. Some 
examples of commercially available or under development cell-based implants 
are shown in Table 5. These cell-based drug delivery systems are used as constant 
producers of bioactive molecules in the form of implant devices. Judging by 
the current developments in this technology, a major driving force behind this 
type of delivery is the improvement in treatment of insulin-dependent diabetes 
mellitus. The biggest challenge in cell-based drug delivery systems is avoiding 
immune response.
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Company Product Application Method of action Manufacture
Neurotech Encapsulated cell therapy 
(ECT)
Ophthalmology Ciliary neurotrophic factor (CNTF) has neuroprotective effects on 
photoreceptors.
Encapsulated human cells producing 
CNTF into the back of the eye.
VIaCyte Encaptra® Stem cell delivery for 
treatment of diabetes 
mellitus
Human stem cells are isolated and differentiated into β islet cells 
contained into a pouch, which is implanted.
PTFE porous membrane device filled 
with cells.
Sernova Cell PouchTM with 
SertolinTM
Diabetes/haemophilia/
thyroid disease
Therapeutic cells are inserted into a pouch made of medical-grade 
materials inserted subcutaneously; Sertolin® is a patented immune 
protection system.
Pouch made of medical-grade 
materials.
PharmaCyte Cell-in-a-box® Pancreatic cancer/breast 
cancer/diabetes
Uses cotton cellulose to encapsulate cells. Single cell encapsulation in 
proprietary polymer, freeze-drying 
process to keep cells viable in the long 
term.
Beta-O2 βAir® bioartificial pancreas Diabetes, adrenal 
insufficiency
Device using alginate—high guluronic acid and high mannuronic 
acid—to encapsulate cells and impregnate a PTFE porous 
membrane, respectively. Also comprises an oxygen-providing 
chamber, which needs refilling.
Single cell encapsulation in 
proprietary polymer, freeze-drying 
process to keep cells viable in the long 
term.
Sigilon Afibromer™ Diabetes Human stem cells differentiated to β islets encapsulated in 
modified alginate spheres, which suppress immune system 
response and FBR.
Encapsulife Encapsulation system for 
the immunoisolation of 
living cells
Diabetes Cellulose-based polymer encapsulation of cells. Pancreatic islets encapsulated are 
stimulated to produce insulin.
Organogenesis 
incorporated
GINTUIT Mucogingival 
conditions
Keratinocytes and fibroblasts produce cytokines and growth 
factors that promote healing and regeneration of the tissue.
Allogeneic keratinocytes and 
fibroblast in bovine collagen.
Table 5. 
Examples of commercially available cell-based implants for drug delivery.
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4.3 Bioactive cellular implants as tissue replacements
When damages due to disease, injury or trauma lead to the degeneration 
of tissues, it is necessary to provide support for their repair, replacement or 
regeneration. Common approaches include tissue transplantation, both from the 
patient’s own body (autograft) and from a donor (allograft). However, harvesting 
autografts is expensive and invasive and the patient may experience infections 
and hematomas. While for the allografts, there are risks of rejection along with 
the infections due to the surgery or the transplanted tissue [158]. With tissue 
engineering, biological implants are developed that restore, maintain and improve 
the tissue function [159]. Implants provide the environment for cell adhesion and 
proliferation to grow new tissues. They can also include active substances like 
growth factors and drugs as well as cells to aid tissue regeneration [11]. Cell-based 
scaffolds are either cultured in vitro with the aim of synthetizing tissues that can 
be implanted, or to be implanted directly in the damaged region [158]. Table 6 
summarises some of the recent studies about cell-based implants tested on in vivo 
models.
4.3.1 Primary cells versus stem cells
The advantage of using cell-based scaffolds is the possibility to customise the 
construct using cells derived from the patient (primary cells). In this way, there is 
no risk of rejection due to immunological incompatibility. Cells can be isolated from 
biopsies and then seeded on the scaffold (Figure 2). However, primary cells are dif-
ferentiated, post-mitotic cells. This leads to a limited lifespan, where after a limited 
number of cell doubling, they will enter in senescence and stop dividing, but are 
still viable [166, 167]. Moreover, primary cell types are difficult to culture, because 
they have difficulties adhering and proliferating in vitro [168].
To overcome problems associated with primary cells, stem cells have been 
be used. Stem cells are present in most if not all tissues and, according to 
their origin, they can be classified into embryonic and adult stem cells. Stem 
cells are able to both duplicate (self-renew) and differentiate in one or more 
cell types [167].
Embryonic stem cells (ESCs) are isolated from inner cell mass of embryo at the 
blastocyst stage. They can differentiate in any cell type (pluripotency) and have a 
high rate of self-renewal. Unfortunately, they can cause an immune response, as 
they are derived from a different body, so immunosuppression is necessary to avoid 
rejection. Moreover, the injection of undifferentiated ESC can lead to the formation 
of teratoma [169].
Adult stem cells (ASCs) are multipotent cells that can differentiate in a limited 
number of cell types, which reside in a specific microenvironment, the stem cell 
niche. Their role is to replace damaged and dead cells in the tissue to maintain 
homeostasis [170].
ASCs can be isolated from bone marrow, blood, adipose tissue, liver and skin 
[169]. Compared to ESCs, ASCs proliferate more slowly and have limited expan-
sion capacity in vitro. Like primary cells, they can enter in senescence [171]. With 
age, their regenerative potential, growth and divisions are affected [172]. The most 
commonly used type of ASCs is mesenchymal stem cells (MSCs). These cells can 
differentiate into musculoskeletal cells, marrow and other cells of connective tissue, 
and they can provide trophic support and modulate the immune response [173]. 
They can migrate to a damaged region and promote healing by secreting molecules 
involved in angiogenesis and cell proliferation and inhibit oxidative stress and 
apoptosis [174, 175].
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Application Cell type Implant Outcome Reference
Tendon 
regeneration
Rat tendon 
stem/progenitor 
cells
Asymmetric 
chitosan-based 
sponges
• Tenogenic specific 
genes expression and 
protein production  
in vitro and in vivo.
• Formation of aligned 
collagen fibres in vivo.
[160]
Neural tissue 
engineering
Schwann 
cells, human 
bone marrow 
mesenchymal 
stem cells 
(BMSCs)
Polyvinyl alcohol 
(PVA)/sulphate 
alginate nanofibers
• Metabolic active cells 
adhered to scaffold.
• Mesenchymal stem 
cells differentiate in 
neuronal cells.
[161]
Wound 
healing 
and skin 
regeneration
Wharton’s jelly 
mesenchymal 
stem cells 
(MSCs)
Poly(ε-
caprolactone) 
(PCL)/gelatin 
nanofibers
• Nanofibrous biode-
gradable scaffolds.
• Cells were metabolic 
active and proliferative 
after 21 days in culture.
• MSCs on the scaffolds 
reduced the presence 
of denaturised proteins 
in vitro, possible 
anti-inflammatory 
response.
[162]
Mandible 
defects repair
Endothelial 
progenitor cells 
(EPCs), BMSCs
Biodegradable 
bioactive glass 
ceramic scaffold
• Expression of osteo-
genesis and angiogen-
esis markers in vitro.
• After 9 months post-
implantation in vivo, 
the defects were nearly 
completely recovered, 
and angiogenesis was 
promoted.
[163]
Acute kidney 
injury
Human 
placenta-derived 
mesenchymal 
stem cells 
(hP-MSCs)
Self-assembling 
peptide hydrogel
• hP-MSCs niche, cell 
survival and angiogen-
esis were promoted in 
in vivo.
• Renal functions were 
ameliorated.
[164]
Spinal cord 
regeneration
Neural stem cells 
(NSCs)
Elastic 
poly(sebacoyl 
diglyceride) 
(PSeD) scaffolds 
coated with 
poly(sebacoyl 
diglyceride)-
isoleucine-
lysinevaline-
alanine-
valine-serine 
(PSeD-IKVAVS)
• Graft-host integration 
in spinal cord in vivo.
• NSCs exhibited neuro-
nal differentiation.
• Inflammatory cells 
infiltrated the lesion 
site, functional recov-
ery after 4 weeks.
• Degradation products 
of PSeD-IKVAVS 
promoted NSCs 
differentiation, 
inhibited neuronal 
apoptosis and allevi-
ated inflammation.
[165]
Table 6. 
Examples of recent studies on cell-based implants.
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Induced pluripotent stem cells (iPSCs) originate from fully differentiated 
somatic cells, which are dedifferentiated to form iPSCs by a process called repro-
gramming. The methodology was developed in 2006 [176] and involves the stimu-
lation of genes that are active during the embryogenesis. Thanks to the cell 
derivation, the implantation of these cells does not lead to rejection. However, as 
with ESCs, iPSCs can form teratoma. Moreover, some of the genes that are activated 
are also associated with tumour development [177].
Figure 2. 
Source of cells used for cell-based implants. Image adapted from [168].
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5. Implant manufacture
To generate tissue replacements, it is essential to resemble the native extra-
cellular matrix (ECM). Therefore, the matrix composition, shape and physical 
properties are crucial. Nanofibers, sponges or gels have been fabricated using 
numerous different techniques or combinations of techniques to mimic the native 
ECMs. Some of these techniques and their biomedical applications are presented 
in Table 7.
5.1 Solvent casting particulate leaching
Solvent casting particulate leaching is a technique developed in 1993 by Mikos 
et al., where a polymer is dissolved in an organic solvent and the polymer solution 
is mixed with an insoluble porogen. The solvent is evaporated by solvent casting 
or freeze-drying techniques. The evaporation leads to a porogen-polymer com-
pound, which is washed to remove the porogen leaving a porous polymer matrix 
behind [187, 188]. This method is relatively easy to use and inexpensive [189]. Pore 
size, porosity and interconnectivity can be controlled selecting the right polymer, 
porogen and their concentration [190].
5.2 Phase separation
Phase separation employs temperature changes that separate the polymeric solu-
tion in two phases: the lean phase (low polymer concentration) and the rich phase 
(high polymer concentration). Briefly, the polymer is dissolved in a solvent, then, 
the temperature is rapidly decreased to have a liquid-liquid separation and two-
phase solid is formed [191]. Finally, the liquid is removed by extraction, evapora-
tion or sublimation [192].
5.3 Freeze-drying
Freeze-drying technique or lyophilisation [193] is based on a sublimation pro-
cess that will produce a porous scaffold. A polymer is added to a mixture of water 
and organic solvent and moved into a mould. The mixture is quickly frozen and, by 
lowering the pressure to few millibars, the water and the organic solvent sublimate. 
The complete removal of the liquid phase takes place under vacuum [189, 194, 
195]. To control porosity and pore size, polymer/water ratio, ionic concentration, 
viscosity and pH, together with freezing rate and temperature, can be changed 
[194, 195].
5.4 Electrospinning
Electrospinning is used to produce micro- and nanofibers. It is widely used 
as it can produce matrix that can resemble the native ECMs. Nanofiber scaffolds 
offer mechanical support and a nanoscale environment for the cells [196, 197]. 
A polymer solution is added to a syringe. Then, high voltage is applied, and the 
solution accelerates to a collector of opposite charge. The solution-air inter-
face changes from rounded to conical, due to the repulsive electrostatic forces 
between the polymer molecules in solution and the attractive force between the 
polymer solution and the collector. The polymer solution is ejected from the 
syringe when the electrostatic forces are higher than the surface tension of 
the solution. Then, the solvent evaporates, and the solid polymer is deposited 
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Technique Material Application Outcome References
Solvent 
casting—
particulate 
leaching
Poly(l-lactic 
acid) (PLLA) 
and matrilin-3 
(MATN3)
Articular 
cartilage 
regeneration
• Nanofibrous porous scaffold.
• Cell hypertrophy and endochon-
dral ossification prevented in vivo.
• Chondrogenesis is promoted  
in vivo.
[178]
Phase 
separation—
particulate 
leaching
Poly(lactic acid) 
(PLA)
Bone tissue 
engineering
• Porous scaffold.
• Osteosarcoma cells (MG63) were 
metabolic active and viable after 
14 days in culture.
[179]
Freeze-drying Poly(ε-
caprolactone) 
(PCL) and zein
Drug 
delivery
• Porous and degradable scaffold.
• Degradation rate increases with 
the concentration of zein.
[180]
Freeze-
drying and 
self-assembly
Collagen Tissue 
engineering
• Aligned collagen scaffolds.
• Rat fibroblasts and neurons 
elongate along aligned fibres.
[181]
Freeze-drying Silk 
fibroin-chitosan
Cartilage 
regeneration
• Porous scaffold.
• MSCs were metabolic active, 
viable and differentiate after 
21 days in culture.
[182]
Electrospinning Poly(ε-
caprolactone) 
(PCL)/poly(d, 
l-lactide-co-
glycolide) 
(PLGA)/gelatin
Vascular 
tissue 
engineering
• Dual-oriented/bilayer hydro-
philic nanofibers.
• Smooth muscle cells and endothe-
lial cells were viable after 7 days; 
orientation along the fibres.
[183]
Electrospinning SiO2CaO Wound 
healing
• Cotton wool-like, fibrous and 
porous scaffold.
• Human fibroblast seeded on 
top were metabolic active and 
proliferative after 7 days in 
culture, and produced vascular 
endothelial growth factor.
[184]
3D printing Copper/tetrakis 
(4-carboxyphenyl) 
porphyrin/β-
tricalcium  
phosphate 
(Cu-TCPP-TCP)
Bone 
tumour 
ablation and 
osteogenesis
• Metal-organic photothermal 
nanosheets.
• Promoted osteosarcoma cell death 
in vitro, ablation of subcutaneous 
bone tumour tissue in vivo.
• Adhesion of bone marrow MSCs 
HUVEC in vitro.
• MSCs differentiated in 
osteocytes.
• HUVEC expressed angiogenesis 
markers in vitro.
• Enhanced bone regeneration in 
vivo.
[185]
E-jet 3D 
printing
Poly(lactic-co-
glycolic acid) 
and drugs 
(5-fluorouracil 
and NVP-BEZ235)
Drug 
delivery in 
orthotopic 
breast cancer
• Long-term drug release near the 
tumour site.
• Less risk for normal tissue.
• No need for several 
administrations.
[186]
Table 7. 
Techniques used for the fabrication of bioactive implants.
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on the collector. By changing the voltage, collector, polymer concentration and 
solvent, it is possible to control the size of the fibres [196, 198].
5.5 Additive manufacturing techniques
Additive manufacturing (AM) techniques, or solid freeform fabrications 
(SFFs), are based on the use of computer-aided design (CAD) to fabricate scaf-
folds. The CAD controls the layer-by-layer deposition of material. The advantage 
of these methods is the full control of the topography of the construct [196, 198].
Three-dimensional (3D) printing is a commonly used AM technique that was 
developed at the Massachusetts Institute of Technology in 1990s [198, 199]. The 
CAD is converted in a stereo lithography (STL) file and exported to the 3D printer 
to control the movement and deposition of the material.
This technique allows the inclusion of cells within the scaffold, as high tem-
perature or solvents are not required for its production [200]. In recent years, 3D 
printing has been used to produce scaffolds and anatomically customised implants 
based on MRI and CT scans. The AM can be classified in three different approaches 
[201], namely laser-based (stereolithography, selective laser sintering, electron 
beam melting and binder jetting) [202–204], nozzle-based (fused deposition 
modelling and melt electrospinning writing) [204–208] and indirect 3D printing 
[209–211].
5.6 Injection moulding
Injection moulding is one of the most commonly used techniques for large-
scale production of thermoplastic items. The plastic is melted and injected into a 
mould of desired shape. When the material solidifies, the mould is removed, and 
the finished part is extracted [212]. Metal constructs can also be fabricated with 
this technique. Metal injection moulding uses fine metal powders mixed with 
a binder and is injected with a conventional thermoplastic moulding machine. 
The binder is then removed, and the product is formed. This method allows the 
production of constructs with a sophisticate shape and higher mechanical proper-
ties [213].
5.7 Self-assembly
Self-assembly is the spontaneous formation of molecular units in supramolecu-
lar structures, without external intervention. These molecules interact through 
hydrogen bonding, van der Waals and electrostatic forces. Due to their biocom-
patibility and biodegradability, peptides are commonly used for self-assembly. 
Specific structure can be created by modifying the amino-acidic composition of 
the peptides [189, 214]. These nanostructures can be used in drug delivery and 
tissue engineering [215].
5.8 Manufacturing considerations
The manufacturing of bioactive implants, whether these are for tissue engi-
neering or for drug delivery purposes, includes several common aspects. These 
include the manufacturing methods that are employed, the biomaterial source, use 
of solvents, scalability, the need for aseptic facilities or if final product sterilisa-
tion is preferred, and if a specifically designed device is needed to administer the 
implant.
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Most importantly, the regulatory strategy for filing needs to be in place soon 
in product development to define all the data that are needed for submission. It is 
important to define if the bioactive implant will be considered a drug product, a 
medical device, or a combination product (drug-device), and in which markets 
should it be launched, as different markets have different regulations and requisites 
for the different categories.
Comprehensive reviews and discussions on the regulatory aspects for filing 
medical devices, and combination products in the biomedical field were reviewed 
[216–218]. Ragelle et al. provide an excellent perspective for nanoparticle-based bio-
materials, its manufacture and regulatory outlook for biomedical engineering [219].
To enable the use in animals and humans, the sterilisation process is impor-
tant. If the manufacturing method is simplified enough, the use of aseptic 
technique for manufacturing, using filters and a particulate-free environment, 
will be possible although costly and complex for significantly large-scale manu-
facturing. For devices where metals are used, sterilisation by moist or dry heat 
may be possible.
However, for implants that involve polymers or heat-sensitive bioactive mol-
ecules, the preferred sterilisation method is gamma-irradiation. The drawback 
of using this technique is the potential risk to polymer and/or bioactive molecule 
degradation, changing the release rate and potentially compromising the efficacy of 
the implant [150]. Depending on the biomaterial and bioactive molecule involved, 
there may be ways to avoid degradation upon gamma-irradiation, such as using an 
antioxidant mixed with the drug. Apart from aseptic conditions, gamma-irradiation 
of the final product remains the best solution but exposes one of the disadvantages 
of developing bioactive implants as it is still a costly technique bringing its own 
risks [220].
6. Summary
In this chapter, we reviewed the current literature about bioactive biomedical 
implants applicable to regenerative therapies and used in drug delivery. To gener-
ate new biomedical implants, biomaterials are continuously developed, either 
through entirely new or by combining advantageous properties of well-known 
and safe biomaterials to improve the application and effectiveness of implants. 
Thus, materials that enhance the natural response of the body and simultane-
ously provide support for cell adhesion and proliferation are required. Another 
field that has developed in recent years is cell-induced bioactivity, where cells 
are used in implants for tissue regeneration and disease treatment. While there 
are several manufacturing techniques to create application-specific bioactive 
implants, new technologies, such as additive manufacturing, bring advantages 
and versatility to the field.
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